595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study

BACKGROUND: Letermovir (LTV) is effective for prevention (ppx) of primary clinically significant CMV infection (csCMVi) in the first 100 days after hematopoietic cell transplant (HCT). Data on LTV for secondary ppx is limited. We report on the efficacy and safety of LTV administered for 14 weeks as...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Gyuri, Stern, Anat, Su, Yiqi, Gyurkocza, Boglarka, Sauter, Craig, Shaffer, Brian, Papanicolaou, Genovefa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644769/
http://dx.doi.org/10.1093/ofid/ofab466.793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644769/
http://dx.doi.org/10.1093/ofid/ofab466.793

Ejemplares similares